Effectiveness of tolvaptan monotherapy and low-dose furosemide/tolvaptan combination therapy for hepatoprotection and diuresis in a rat cirrhotic model

Spironolactone and furosemide, which are used to treat ascites associated with decompensated cirrhosis, are ineffective in treating refractory ascites. Hence, combination therapy with tolvaptan, a vasopressin V2 receptor antagonist, has been approved in Japan. Tolvaptan monotherapy and combination t...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanabe, Norikazu, Takami, Taro, Fujisawa, Koichi, Matsumoto, Toshihiko, Yamamoto, Naoki, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525014/
https://www.ncbi.nlm.nih.gov/pubmed/28751810
http://dx.doi.org/10.3164/jcbn.16-122

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525014/
https://www.ncbi.nlm.nih.gov/pubmed/28751810
http://dx.doi.org/10.3164/jcbn.16-122

Ejemplares similares